Neurophysiological Effects of Medication Tapering During Treatment With Spinal Cord Stimulation

Inclusion Criteria: * Patient deemed a suitable candidate for SCS and routinely scheduled to undergo a trial phase with the Evoke SCS system. * Diagnosis of Persistent Spinal Pain Syndrome Type 2 (lower spine). * Current medication use: * No strong opioids or anticonvulsants, or other analgesics * Monotherapy with a strong opioid, or * Monotherapy with an anticonvulsant. * Willing and able to provide written informed consent to participate, based on a voluntary agreement after a full explanation of the study. * Age ≥ 18 years at the time of enrollment. * Willing and able to comply with study requirements, procedures, and follow-up visits. Exclusion Criteria: * Evidence of an active disruptive psychological or psychiatric disorder, or other condition significant enough to impact pain perception, compliance with intervention, or ability to evaluate outcomes (as determined by the investigator in consultation with a clinical psychologist). * Current diagnosis of a progressive neurological disease such as multiple sclerosis, chronic inflammatory demyelinating polyneuropathy, rapidly progressive arachnoiditis, rapidly progressive diabetic peripheral neuropathy, brain or spinal cord tumor, or severe/critical spinal stenosis. * Current diagnosis or condition such as coagulation disorder, bleeding diathesis, platelet dysfunction, progressive peripheral vascular disease, or uncontrolled diabetes mellitus that presents excess risk for the procedure (as determined by the investigator). * Active systemic or local infection. * Pregnancy. * Within 6 months prior to enrollment: significant untreated addiction to dependency-producing medications or a history of substance abuse (including alcohol or illicit drugs).